CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kanbak, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kanbak, M.

Canadian Journal of Anesthesia, Vol 46, 581-585, Copyright © 1999 by Canadian Anesthesiologists' Society

ARTICLES

The treatment of heparin resistance with Antithrombin III in cardiac surgery

M Kanbak
Department of Anaesthesiology and Reanimation, Hacettepe University, Faculty of Medicine, Ankara, Turkey. ok05-k@tr-net.net.tr

PURPOSE: To report three patients who developed heparin resistance during cardiac surgery which was successfully managed with 1000 U Antithrombin III (AT III). CLINICAL FEATURES: We observed heparin resistance prior to cardiopulmonary bypass (CPB) in one patient and during the CPB in two patients. In the first patient who was scheduled for mitral valve replacement, although heparin was administered sequentially up to 500 U x kg(-1) prior the CPB, the ACT value was 354 sec. After 1,000 U ATIII were administered the ACT was 395 sec and CPB was initiated. The ACT remained between 496 and 599 sec throughout CPB and a total of 260 mg protamine sulfate was given. In the other two patients following 300 U x kg(-1) heparin, the ACT was up to 400 sec and CPB was initiated. During CPB, ACT were decreased 360 sec and 295 sec in patients II and III respectively. Although heparin was added 1,500 U, ACT increased to > or = 400 sec could not be achieved. In the second patient ATIII activity was found 10%. After the administration of 1,000 U ATIII, ATIII activity was found to be 67% 40 min later and ACT were increased up to 400 sec. There was no thrombosis within the extracorporeal circuit, additional heparin was not required, less protamine was administered (< or = 3 mg x kg(-1)) and no excessive postoperative bleeding was observed in all patients. CONCLUSION: We recommend that AT III supplementation should be considered to manage heparin resistance prior or during CPB in patients undergoing open heart surgery.


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
J. M. Rodriguez-Lopez, E. del Barrio, F. S. Lozano, and C. Muriel
Does Preoperative Level of Antithrombin III Predict Heparin Resistance During Extracorporeal Circulation?
Anesth. Analg., October 1, 2008; 107(4): 1444 - 1445.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. D. Spiess
Treating heparin resistance with antithrombin or fresh frozen plasma.
Ann. Thorac. Surg., June 1, 2008; 85(6): 2153 - 2160.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
J. H. Levy, F. Montes, F. Szlam, and C. D. Hillyer
The In Vitro Effects of Antithrombin III on the Activated Coagulation Time in Patients on Heparin Therapy
Anesth. Analg., May 1, 2000; 90(5): 1076 - 1079.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Canadian Anesthesiologists' Society.